Evidence map›Paper›PMID 35565178›Full record

ArticleCancers2022

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis.

Miriam Recalde, María Gárate-Rascón, José María Herranz, María Elizalde, María Azkona, Juan P Unfried, Loreto Boix, María Reig, Bruno Sangro, Maite G Fernández-Barrena and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Miriam RecaldeProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-5485-1420
María Gárate-RascónProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
José María HerranzProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-6031-535X
María ElizaldeProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
María AzkonaProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
Juan P UnfriedDepartment of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-4005-8800
Loreto BoixNational Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), 28029 Madrid, Spain.
María ReigNational Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), 28029 Madrid, Spain.ORCID 0000-0002-5711-9534
Bruno SangroNational Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), 28029 Madrid, Spain.ORCID 0000-0002-4177-6417
Maite G Fernández-BarrenaProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-0375-6236
Puri FortesNational Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), 28029 Madrid, Spain.ORCID 0000-0001-7571-6220
Matías A ÁvilaProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6570-3557
Carmen BerasainProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-7075-2476
María ArechederraProgram of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-4830-1924
Instituto de Salud Carlos III · ESUniversidad de Navarra · ES

Funding

Fundación Científica Asociación Española Contra el Cáncer POSTD18014ARECGobierno de Navarra 55/2018Instituto de Salud Carlos III PI19/00163Instituto de Salud Carlos III PI19/00742Ministerio de Ciencia, Innovación y Universidades BES-2017-079883Ministerio de Ciencia, Innovación y Universidades FPU18/01461Ministerio de Ciencia, Innovación y Universidades PID2019-104265RBI00/AEI/10.13039/501100011033Ministerio de Ciencia, Innovación y Universidades PID2019-104878RB-100AEI/10.13039/501100011033Ministerio de Ciencia, Innovación y Universidades RYC2018-024475-1Ministerio de Ciencia, Innovación y Universidades UE/RTI2018-101759-B-I00
6 · The paper itself

Abstract

backgroundLong noncoding RNAs (lncRNAs) are emerging as key players in cancer, including hepatocellular carcinoma (HCC). Here we identify the mechanism implicated in the HCC inhibition of a set of lncRNAs, and their contribution to the process of hepatocarcinogenesis. METHODS AND

resultsThe top-ranked 35 lncRNAs downregulated in HCC (Top35 LNDH) were validated in several human HCC cohorts. We demonstrate that their inhibition is associated with promoter hypermethylation in HCC compared to control tissue, and in HCC human cell lines compared to primary hepatocytes. Moreover, demethylating treatment of HCC human cell lines induced the expression of these lncRNAs. The Top35 LNDH were preferentially expressed in the adult healthy liver compared to other tissues and fetal liver and were induced in well-differentiated HepaRG cells. Remarkably, their knockdown compromised the expression of other hepato-specific genes. Finally, the expression of the Top35 LNDH positively correlates with the grade of tumor differentiation and, more importantly, with a better patient prognosis.

conclusionsOur results demonstrate that the selected Top35 LNDH are not only part of the genes that compose the hepatic differentiated signature but participate in its establishment. Moreover, their downregulation through DNA methylation occurs during the process of hepatocarcinogenesis compromising hepatocellular differentiation and HCC patients' prognosis.

Indexed as

DNA methylationepigeneticshepatocellular carcinomahepatocellular differentiationlncRNAsprognosis

Identifiers

PMID35565178
PMCPMC9102946
OpenAlexW4224282213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.